{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-141098","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2025-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.756737+00:00","generated_at":"2026-05-19T06:27:02.716917+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Roche to advance prasinezumab to Phase III for Parkinson’s; Phase IIb data missed primary endpoint","bullets":["Partner Roche advancing prasinezumab into Phase III for early-stage Parkinson’s disease.","Phase IIb PADOVA study missed statistical significance on primary endpoint but showed positive trends in motor progression.","Open-label extension data suggest sustained clinical benefit over longer treatment periods.","First biomarker evidence from PADOVA indicates impact on underlying disease biology.","Over 10 million people affected globally; potential first disease-modifying treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-141098","json":"https://secwatch.observer/filing/0001193125-25-141098.json","markdown":"https://secwatch.observer/filing/0001193125-25-141098.md","text":"https://secwatch.observer/filing/0001193125-25-141098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000119312525141098/0001193125-25-141098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000119312525141098/d13247d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T06:27:02.716917+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}